

Reference FOI202122418

Number:

From: Other

Date: 29 December 2021

Subject: Paediatric antibiotic guidelines

The UK Paediatric Antimicrobial Stewardship Committee is currently trying to assess and improve antibiotic prescribing in the UK. We are asking all Trusts to provide a copy of their inpatient paediatric antibiotic guideline. Please provide a copy of the inpatient paediatric antibiotic guideline at Alder Hey Hospital.

A1 Please see attached document: FOI418 Antimicrobial Prescribing Guidelines



Antimicrobial Prescribing Guidelines



CONTENTS


| PART 1: EMPIRICAL TREATMENT GUIDELINES | |
|--|---|
| START SMART - THEN FOCUS: SUMMARY OF BEST PRACTICE FOR ANTIMICROBIAL TREATMENT | |
| GENERAL ANTIMICROBIAL PRESCRIBING ADVICE | |
| HIGH DOSE ANTIBIOTICS | |
| ADHERENCE AND PALATABILITY | |
| | |
| | |
| SEPSIS | 1 |
| SEPSIS (COMMUNITY ACQUIRED) | 1 |
| SEPSIS (HOSPITAL ACQUIRED) WITHOUT A CENTRAL LINE | |
| SUSPECTED CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION (CLABSI) | |
| CONFIRMED CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION (CLABSI) | |
| BONE AND JOINT INFECTIONS | 1 |
| OSTEOMYELITIS AND SEPTIC ARTHRITIS | |
| CARDIOVASCULAR INFECTIONS | 1 |
| INFECTIVE ENDOCARDITIS | |
| CENTRAL NERVOUS SYSTEM INFECTIONS | 1 |
| MENINGITIS | 1 |
| NEUROSURGERY ANTIBIOTIC TREATMENT GUIDELINES | 1 |
| DENTAL AND MAXILLOFACIAL INFECTIONS | |
| DENTAL ABSCESS | 2 |
| SALIVARY GLAND INFECTION | 2 |
| EAR, NOSE AND THROAT INFECTIONS | |
| ACUTE OTITIS MEDIA | 2 |
| EPIGLOTTITIS | 2 |
| SINUSITIS | 2 |
| ACUTE LYMPHADENITIS | 2 |
| ACUTE MASTOIDITIS | |
| CHRONIC MASTOIDITIS | 2 |
| TONSILLITIS | |
| PERI-TONSILLAR ABSCESS / RETRO-PHARYNGEAL ABSCESS | |
| GASTRO-INTESTINAL INFECTIONS | |
| CLOSTRIDIOIDES DIFFICILE INFECTION | |
| INTRA-ABDOMINAL INFECTION | |
| NECROTISING ENTEROCOLITIS | |
| RESPIRATORY TRACT INFECTIONS | |
| COMMUNITY ACQUIRED PNEUMONIA | |
| ASPIRATION PNEUMONIA | |
| HOSPITAL ACQUIRED PNEUMONIA AND COMPLEX CASES | |
| EMPYEMA | |
| INFECTIONS IN CYSTIC FIBROSIS | |
| INFI LIENZA | 2 |

| SKIN AND SOFT TISSUE INFECTIONS | 29 |
|---|----|
| BURNS – TREATMENT OF INFECTED BURNS | 29 |
| CELLULITIS, ERYSIPELAS, FURUNCLE, SKIN ABSCESS, IMPETIGO | |
| NECROTISING FASCIITIS | |
| PRE-SEPTAL CELLULITIS and ORBITAL CELLULITIS | |
| BITES (HUMAN AND ANIMAL) | 30 |
| SURGICAL SITE INFECTIONS. | |
| URINARY TRACT INFECTIONS | |
| CYSTITIS / LOWER UTI | |
| COMPLICATED UTI (UPPER UTI/ UROSEPSIS) | |
| | |
| | |
| Part II:_SURGICAL PROPHYLAXIS GUIDELINES | 33 |
| GENERAL PRINCIPLES OF SURGICAL PROPHYLAXIS | 34 |
| ANTIBIOTIC DOSES AND REDOSING ADVICE FOR SURGICAL PROPHYLAXIS | |
| CARDIAC SURGICAL PROPHYLAXIS GUIDELINES | |
| CARDIAC PACEMAKER INSERTION | |
| CLEFT LIP AND PALATE SURGICAL PROPHYLAXIS | |
| EAR, NOSE AND THROAT SURGICAL PROPHYLAXIS | |
| GASTRO-INTESTINAL SURGICAL PROPHYLAXIS | |
| NEUROSURGERY AND CRANIOFACIAL SURGICAL PROPHYLAXIS | |
| ORTHOPAEDIC AND SPINAL SURGICAL PROPHYLAXIS | |
| URO-GENITAL SURGICAL PROPHYLAXIS | 45 |
| | |
| | |
| Appendix I:_RESTRICTED ANTIMICROBIALS | |
| restricted antimicrobials | |
| restricted antimicrobials dose information | 48 |
| | |
| | |
| REFERENCES | 49 |

PART I: EMPIRICAL TREATMENT GUIDELINES

START SMART - THEN FOCUS: SUMMARY OF BEST PRACTICE FOR ANTIMICROBIAL TREATMENT

<u>Start Smart - Then Focus</u> is a key Department of Health publication on best practice of antimicrobial prescribing. The key recommendations for antimicrobial treatment are summarised in the algorithm below.



GENERAL ANTIMICROBIAL PRESCRIBING ADVICE

- Do not start antimicrobials in the absence of clinical evidence of bacterial infection, and document the indication for the antimicrobial on the prescription.
- Initiate prompt treatment with effective antimicrobials for sepsis and severe or life-threatening infections as soon as possible and always within one hour of presentation.
- Use antimicrobials with an adequate spectrum of cover for the likely pathogens for less severe infections.
- If the child is <1 month and the local guidelines do not give specific recommendations for this age group, treat as per Sepsis of Unknown Origin guideline.
- Always use the optimal dosing regimen for the clinical indication and the patient's individual parameters.
- Consider the risk of resistant pathogens (e.g. MRSA or ESBL-producing organisms) and offer alternative treatment regimens accordingly, or seek advice from Infectious Diseases / Microbiology.
- Confirm allergy status and offer alternative treatment choices for patients intolerant of recommended antimicrobial agents. Patients with a history of anaphylaxis, urticaria or rash immediately after penicillin administration should not receive a penicillin, cephalosporin or other β-lactam antibiotic. If an alternative has not been suggested in this document, please discuss alternative antibiotic treatment with Infectious Diseases / Microbiology.
- Ensure that the appropriate specimens are taken for culture and sensitivity testing prior to commencing antibiotic treatment without causing delay to starting treatment in patients with severe sepsis or life-threatening infections.
- Consider intravenous (IV) administration only to patients who are severely ill, unable to tolerate oral treatment, or where oral therapy would not provide adequate coverage or tissue penetration (e.g. CNS infection).
- For infections listed as 'H' on Meditech microbiology report please see High Dose Antibiotic Table on page 7
- Document the next review date or stop date on the prescription.
- It is essential to review antimicrobial prescriptions after 48-72 hours, and after a clinical review and checking microbiology results, a clear plan should be documented in the case notes, which should be:
 - 1) Stop 2) IV to oral Switch 3) Change antibiotic 4) Continue and review again in 72 hours or 5) Out-patient Parenteral Antibiotic Therapy (OPAT).

HIGH DOSE ANTIBIOTICS

This information is intended to provide dosing guidance when infections are reported as 'H' on the Meditech microbiology report. A susceptibility category of 'H' indicates that specific dosing is required in order for the antibiotic to effectively treat the infecting organism.

The doses advised in this reference are appropriate for patients with normal renal and hepatic function. If there is known or suspected renal or hepatic impairment please contact pharmacy for further advice.

Some of these doses may not be appropriate for patients at extremes of bodyweight – please consider accordingly and if necessary contact pharmacy for further advice.

| ANTIBIOTIC | ROUTE OF ADMINISTRATION | PATIENT AGE | RECOMMENDED HIGH DOSE |
|-------------|-------------------------|-------------------------------------|---|
| Amikacin | Intravenous | All ages | None – refer to aminoglycoside pathway *Must not be used as single agent* |
| | | Neonate up to 7 days | 50mg/kg* every 12 hours |
| | | Neonate 7 days to 28 days | 50mg/kg* every 8 hours |
| | la traves a pare | * For mening | itis please refer to the BNFc |
| | Intravenous | Child (up to 40kg) | 50mg/kg (max 2g) every 4 hours |
| Amoxicillin | | Adult (40kg and above) | 2g every 4 hours |
| | | Neonate 7 days to 28 days | 30mg/kg (max 125mg) 3 times a day |
| | Oral | Child 1 month – 4 years | 30mg/kg 3 times a day |
| | Oldi | Child 5 – 11 years | 30mg/kg (max 1g) 3 times a day |
| | | Child 12 years - Adult | 1g 3 times a day |
| | Intravenous | Neonate up to 7 days | 30mg/kg every 12 hours |
| Aztreonam | | Neonate 7 days – Child 23 months | 30mg/kg every 6 hours |
| | | Child 2-11 years | 50mg/kg (max 2g) every 6 hours |
| | | Child 12 years - Adult | 2g every 6 hours |
| | | Neonate up to 7 days | 50mg/kg every 24 hours |
| | | Neonate 7 to 20 days | 50mg/kg every 12 hours |
| Ceftazidime | Intravanaus | Neonate 21 to 28 days | 50mg/kg every 8 hours |
| Cerraziaime | Intravenous | Child (up to 40kg) | 50mg/kg (max 2g) every 8 hours |
| | | Adult (40kg and above) | 2g every 8 hours |
| | | Neonate up to 7 days | 50mg/kg every 12 hours |
| | | Neonate 7 days to 20 days | 50mg/kg every 8 hours |
| Cefuroxime | Intravenous | Neonate 21 days to 28 days | 50mg/kg every 6 hours |
| Ceturoxime | Intravenous | Child (1month – 30kg) | 50mg/kg (max 1.5g) every 8hours |
| | | Adult (30kg and above) | 1.5g every 8 hours |

| | | Neonate | 10mg/kg every 12 hours |
|-----------------------------|---------------------|--|---|
| | Intravenous | Child | 10mg/kg (max 400mg) every 8 hours |
| O: 11 : | | Adult | 400mg every 8 hours |
| Ciprofloxacin | | Neonate | 15mg/kg BD |
| | Oral | Child | 20mg/kg (max 750mg) BD |
| | | Adult | 750mg BD |
| | | Neonate | 30mg/kg every 12 hours |
| | Introvenous | Child 1-2 months | 30mg/kg every 12 hours |
| | Intravenous | Child 3 months – 17 years | 30mg/kg (max 1.2g) every 8 hours |
| | | Adult | 1.2g every 8 hours |
| Co-Amoxiclav | | Child 2 – 23 months | 0.3mL/kg BD of 400/57 oral suspension |
| | | Child 2 – 6 years (13 – 21kg) | 5mL BD of 400/57 oral suspension |
| | Oral | Child 7 – 12 years (22 – 40kg) | 10mL bd of 400/57 oral suspension |
| | | Child 12 years – Adult (41kg and above) | 10mL TDS using 400/57 suspension |
| | Intravenous Oral | Child 6 weeks – 17 years | 27mg/kg (max 1.44g) every 12 hours |
| | | Adult | 1.44g every 12 hours |
| Co- Trimoxazole** | | 6 weeks –11 years | 24mg/kg BD |
| | | 12 years - Adult | 960mg BD |
| | | **For Pneumocystis jirovecii | (PCP) infection please refer to the BNFc |
| Gentamicin | Intravenous | All ages | None – as per aminoglycoside pathway *Must not be used as a single agent* |
| | | Neonate up to 7 days | 40mg/kg every 12 hours as extended 3 hour infusion*** |
| Meropenem | Intravenous | Neonate 7 days — Child (up to 50kg) | 40mg/kg every 8 hours as extended 3 hour infusion*** |
| | | Child (50kg and above) – Adult | 2g every 8 hours as extended 3 hour infusion*** |
| | | Neonate | 90mg/kg every 8 hours given as an extended 3 hour infusion*** |
| Piperacillin- Tazobactam | Intravenous | Child 1 month – 11 years (up to 50kg) | 90mg/kg (max 4.5g) every 6 hours given as an extended 3 hour infusion*** |
| | | Child 12 years - Adult (50kg and above) | 4.5g every 6 hours (max dose 4.5g every 6 hours) given as an extended 3 hour infusion*** |

^{***} For antibiotics requiring administration as an extended 3 hour infusion please document this as a <u>dose</u> <u>instruction</u> on the Meditech 6 prescription and refer nursing staff to the Paediatric Injectable Therapy Guidelines for further information.

ADHERENCE AND PALATABILITY

The choice of oral antibiotic should account for factors potentially affecting adherence such as dosing frequency and palatability/taste of formulation. Palatable oral drugs in a sensible regimen (up to 3 times per day) should be used where possible, and middle of the night dosing of oral antibiotics should be avoided whenever possible, especially following discharge.

Oral liquids which should be avoided due to poor palatability include:

- Flucloxacillin oral liquid: consider using oral cefalexin liquid if patient cannot swallow flucloxacillin capsules
- Clindamycin oral liquid: consider using an alternative (may need to discuss suitable alternatives with Pharmacy or Infectious Diseases/Microbiology)

SEPSIS (COMMUNITY ACQUIRED)

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------|---|--|---|---|---|
| Birth-1 month | Group B Streptococcus Escherichia coli Listeria monocytogenes Haemophilus influenzae Streptococcus pneumoniae Klebsiella spp. Salmonella spp. Staphylococcus aureus Enterococcus spp. | IV <u>Cefotaxime</u> + IV <u>Amoxicillin</u> * | IV <u>Cefotaxime</u> refer to BNFc IV Amoxicillin: less than 7 days: 50mg/kg/dose every 12 hours 7-28 days: 50mg/kg/dose every 8 hours | Review at 36-48 hours and consider stopping antibiotics. Culture negative sepsis: Up to 5 days Culture positive sepsis: See appropriate | Obtain appropriate cultures before starting antibiotic treatment as soon as possible, and always within 1 hour of presentation. Check previous microbiology results to determine if recent antibiotic-resistant organisms have been identified and contact the Infectious Diseases / Microbiology if: - patient has a previous history of carriage or infection with antibiotic-resistant organisms (e.g. Extended Spectrum Beta-Lactamase (ESBL) expressing organisms) - prolonged/multiple antibiotic use in the previous 3 months - patient has been overseas in the previous 3 months Once causative organism is known (usually within 24 hours) antibiotic choice and duration should be amended if necessary. |
| 1 month and above | Escherichia coli Haemophilus influenzae Streptococcus pneumoniae Klebsiella spp. Salmonella spp. Staphylococcus aureus Neisseria meningitidis | IV <u>Cefotaxime</u> Unless immunosuppression: Use oncology febrile neutropenia guidance on antimicrobials | IV <u>Cefotaxime</u> 50mg/kg (max 3g) every 6 hours | guidance below. *Stop amoxicillin at 36 hours once Listeria meningitis is excluded. | |

If IV access is unavailable, if appropriate, prescribe IM ceftriaxone until IV access obtained.

For preterm neonates less than 41 weeks corrected gestational age ceftriaxone is contraindication so prescribe IM cefotaxime instead.

Note: Intramuscular injections should only be prescribed if safe to do, eg, patients with low platelets may not be suitable.

SEPSIS (HOSPITAL ACQUIRED) WITHOUT A CENTRAL LINE

Greater than 4 days hospitalisation

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES | | | | | | | | | | | | | | | | | | | | |
|-----------------------|--|--|---|---|---|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--|--|---|---|--|---|--|---|---|--|---|--|--|--|---|
| Less than 3 months | Staphylococcus aureus Enterococcus spp. Enterobacteriaceae Pseudomonas spp. | IV <u>Vancomycin</u> plus IV <u>Ciprofloxacin</u> | IV <u>Vancomycin</u> : refer to local Vancomycin Dosing and Monitoring Guidelines on the intranet IV <u>Ciprofloxacin</u> : refer to BNFc | Review at 36-48 hours and consider stopping antibiotics. | hours and consider stopping | hours and consider stopping | hours and consider stopping | hours and consider stopping | hours and consider stopping | hours and consider stopping | Review at 36-48 hours and consider stopping antibiotics. | Review at 36-48 hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | Review at 36-48 hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | Review at 36-48 hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | hours and consider stopping antibiotics. | Obtain appropriate cultures before starting antibiotic treatment as soon as possible, and always within 1 hour of presentation. Check previous microbiology results to determine if recent antibiotic-resistant organisms have been identified and contact the Infectious Diseases / Microbiology if: - patient has a previous history of carriage or infection with antibiotic-resistant organisms (e.g. Extended Spectrum Beta-Lactamase (ESBL) expressing organisms) |
| 3 months and above | Staphylococcus aureus Enterococcus spp. Enterobacteriaceae Pseudomonas spp. | IV <u>Teicoplanin</u> plus IV <u>Ciprofloxacin</u> | IV <u>Teicoplanin</u> : loading dose 10mg/kg (max 800mg) every 12 hours for 3 doses, followed 24 hours later by a maintenance dose of 10mg/kg (max 800mg) once daily IV <u>Ciprofloxacin</u> : refer to BNFc | Culture negative sepsis: Up to 5 days Culture positive sepsis: See appropriate guidance below. | prolonged/multiple antibiotic use in the previous 3 months patient has been overseas in the previous 3 months Once causative organism is known (usually within 24 hours) antibiotic choice and duration should be amended if necessary. | | | | | | | | | | | | | | | | | | | | |

SUSPECTED CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION (CLABSI)

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION | NOTES |
|-----------------------|--|---|---|-------------|--|
| Less than 3 months | Coag. negative Staphylococci Staphylococcus aureus Enterococcus spp. Enterobacteriaceae | IV <u>Vancomycin</u> plus IV <u>Ciprofloxacin</u> | IV <u>Vancomycin</u> : refer to local Vancomycin Dosing and Monitoring Guidelines on the intranet IV <u>Ciprofloxacin</u> : refer to BNFc | 7 - 14 days | Obtain blood cultures from the central line before starting antibiotic treatment. Start antibiotics as soon as possible, and always within 1 hour of presentation. Check previous microbiology results to determine if recent antibiotic-resistant organisms have been identified and contact the Infectious Diseases / |
| 3 months and above | Coag. negative Staphylococci Staphylococcus aureus Enterococcus spp. Enterobacteriaceae | IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> Unless immunosuppression: Use oncology febrile neutropenia guidance on antimicrobials | IV <u>Teicoplanin</u> : loading dose 10mg/kg (max 800mg) every 12 hours for 3 doses, followed 24 hours later by a maintenance dose of 10mg/kg (max 800mg) once daily IV <u>Gentamicin</u> : refer to local Aminoglycoside Dosing and Monitoring Guidelines on the intranet | 7 - 14 days | Microbiology if: - patient has a previous history of carriage or infection with antibiotic-resistant organisms (e.g. Extended Spectrum Beta-Lactamase (ESBL) expressing organisms) - prolonged/multiple antibiotic use in the previous 3 months - patient has been overseas in the previous 3 months Repeat Blood Cultures should be taken from CVC when the laboratory calls to say there is a positive blood culture. Two positive blood cultures with the same organism are highly suggestive of CVC infection. Blood cultures (both CVC and peripheral) should also be repeated if fever persists and the child is not improving clinically. Review choice and duration of antibiotic therapy when culture and sensitivities are available, see next page. |

CONFIRMED CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTION (CLABSI)

| ORGANISM | CHOICE OF ANTIMICROBIAL | CHOICE OF LINE-LOCK | DURATION (from last negative blood culture) |
|------------------------------------|---|----------------------------|---|
| Enterococcus spp. | IV <u>Amoxicillin</u> if sensitive PLUS Vancomycin line-locks Or IV <u>Teicoplanin</u> OR IV <u>Vancomycin</u> , PLUS Vancomycin line-locks | Vancomycin line-locks | 7 - 10 days |
| Coagulase negative Stapylococci | IV <u>Teicoplanin</u> Or IV <u>Vancomycin</u> | Vancomycin line-locks | 7 - 10 days |
| Staphylococcus aureus | IV <u>Flucloxacillin</u> | Vancomycin line locks | 14 days |
| MRSA | IV <u>Vancomycin</u> (see also MRSA policy) | Vancomycin line-locks | 14 days |
| Gram negative organisms | Refer to ID / microbiology | Refer to ID / microbiology | 10 – 14 days |
| Candida spp | IV <u>Liposomal Amphotericin</u> | - | 14 days |

Prompt removal of all non-tunnelled venous catheters associated with confirmed blood stream infection is recommended.

Antibiotic Line-lock Therapy improves the chance of saving the Central Venous Catheter (CVC). Line locks are not useful in CVCs which have been inserted <14 days previously. Bacteria in a biofilm within the lumen of the CVC need high concentrations of antibiotics to kill them. Antibiotic line-lock should be locked into the catheter lumen for as long as possible (up to 24 hours), during periods when the catheter is not being used. The antibiotic lock should be aspirated before the line is used for other infusions.

The amount instilled should be equivalent to the priming volumes printed on the catheter or clamp, but as a guide, the volume of antibiotic line locks prescribed should be no more than 1ml for children under 2 years, and 2ml for children 2 years and above:

| Antibiotic Line-Lock | Concentration | Preparatory notes |
|-----------------------------|---------------|---|
| Amikacin | 2mg/ml | Withdraw 0.4mL from a 100mg/2mL ampoule and further dilute to 10mL with sodium chloride 0.9% to give a 2mg/mL solution. |
| Ciprofloxacin | 2mg/ml | Use neat 2mg/ml injection solution |
| Gentamicin | 1mg/ml | Withdraw 1ml from a Gentamicin 20mg/2ml ampoule and further dilute to 10ml with Sodium Chloride 0.9% to produce a 1mg/ml solution. |
| Vancomycin | 5mg/ml | Reconstitute 500mg vial of vancomycin with water for injections as described in the local injectable therapy guidelines to give a 50mg/mL solution. Further dilute 1mL of the 50mg/mL solution to 10mL with sodium chloride 0.9% to give a 5mg/mL solution. |

BONE AND JOINT INFECTIONS

OSTEOMYELITIS AND SEPTIC ARTHRITIS

Unifocal disease indicates "simple" disease at a single site, whereas **Complex** disease includes any of the following: multifocal, significant bone destruction, resistant or unusual pathogen, immunosuppression.

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|--------------------------|---|---|--|--|--|
| Birth-3 months | Group B Streptococcus Staphylococcus aureus Kingella kingae | IV <u>Cefotaxime</u> + IV <u>Flucloxacillin</u> * | Refer to BNFc and use maximum doses allowed according to age and weight | 4-6 weeks | Consider IV to oral switch after 14 days for unifocal disease and after 21 days in complex disease. Considerations for IV to oral switch: clinical improvement, afebrile and oral fluids and medication can be established and CRP<20 or decreased by 66% of the highest value. Oral antibiotic choice based on microbiology culture and sensitivity results, or if an organism has not been identified, use cefalexin as an oral stepdown and use the maximum dose allowed according to age/weight. *IV Clindamycin in penicillin allergy. |
| 3 month to 5 years | Staphylococcus aureus Group B Streptococcus Kingella kingae | IV <u>Cefuroxime</u> | IV <u>Cefuroxime</u> 50mg/kg (max. 1.5g) every 6 hours | 3 weeks for septic arthritis 4-6 weeks in unifocal osteomyelitis At least 6 weeks in complex osteomyelitis | In unifocal disease consider IV to oral switch after 48 hours. In complex disease consider IV to oral switch after 14 days unless there is significant bone destruction as this often requires more than 6 weeks of IV antibiotics. Considerations for IV to oral switch: clinical improvement, afebrile and oral fluids and medication can be established and |
| 5 years and above | Staphylococcus aureus Streptococcus spp. | IV <u>Flucloxacillin</u> * | IV <u>Flucloxacillin</u> 50mg/kg (max. 2g) every 6 hours | 3 weeks for septic arthritis 4-6 weeks in unifocal osteomyelitis At least 6 weeks in complex osteomyelitis | CRP<20 or decreased by 66% of the highest value. Oral antibiotic choice based on microbiology culture and sensitivity results, or if an organism has not been identified, use cefalexin as an oral stepdown and use the maximum dose allowed according to age/weight. *IV Clindamycin in penicillin allergy. |

CARDIOVASCULAR INFECTIONS

INFECTIVE ENDOCARDITIS

If endocarditis suspected; obtain 3 blood cultures by separate venipunctures on the first day, if there is no growth by the second day of incubation, obtain 2 or 3 more. In patients who are not acutely ill and whose blood culture remain negative, withholding antibiotic drugs for 48 hours or more while additional blood cultures are obtained may be considered to determine the cause of endocarditis.

In patients who are severely ill and unstable, 3 separate venipunctures for blood cultures should be performed over 1 to 2 hours.

Contact Infectious Diseases / Microbiologist for advice, and refer to the American Heart Association Scientific Statement: Infective Endocarditis in Childhood

MENINGITIS Please refer to Guidelines for the Management of Suspected Bacterial Meningitis and Septicaemia for guidance on recognition, investigation and management

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | nd Septicaemia for guidance on recognition, investigation and management NOTES |
|-------------------------|--|--|---|---|---|
| Birth-1 month | Group B Streptococcus Escherichia coli Listeria monocytogenes Neisseria meningitidis Haemophilus influenzae Streptococcus pneumoniae Herpes simplex virus Varicella zoster virus | IV <u>Cefotaxime</u> + IV <u>Amoxicillin</u> * | Refer to BNFc and use maximum dose allowed according to age and weight | See table below (ages 0-1 month) | Obtain appropriate cultures before starting antibiotic treatment. Start antibiotics within 1 hour of diagnosis for life threatening infections. Add IV Aciclovir only if seizures, focal neurological symptoms or known exposure to HSV infection. Continuation of aciclovir must be reviewed by a Consultant within 24 hours. Once causative organism is known (usually possible after 24 hours) therapy must be adjusted according to table below. *Stop amoxicillin once Listeria meningitis is excluded. Contact the Infectious Diseases / Microbiology team if: - causative organism cannot be identified - patient has history of prolonged/multiple antibiotic use Bacterial meningitis is a notifiable disease. The local Public Health England team should be informed by phone within 24 hours to co-ordinate chemoprophylaxis (see page 14 for contact details). |
| 1 month and above | Neisseria meningitidis Haemophilus influenzae Streptococcus pneumoniae | IV <u>Cefotaxime</u> | IV <u>Cefotaxime</u> 50mg/kg (max 3g) every 6 hours | Depends on organism (see notes**) | Obtain appropriate cultures before starting antibiotic treatment. Start antibiotics within 1 hour of diagnosis for life threatening infections. Add IV Aciclovir only if seizures, focal neurological symptoms or known exposure to HSV infection. Continuation of aciclovir must be reviewed by a Consultant within 24 hours. **Duration of cefotaxime depends on causative organism (7 days for N. meningitidis, 10 days for H. influenzae and 14 days for S. pneumoniae). Contact the Infectious Diseases / Microbiology team if: - patient has previous history of carriage or infection with antibiotic-resistant organisms causative organism cannot be identified - patient has been overseas in the previous 3 months - patient has had prolonged/multiple antibiotic use in the previous 3 months. Bacterial meningitis is a notifiable disease. The local Public Health England team should be informed by phone within 24 hours to co-ordinate chemoprophylaxis (see page 14 for contact details). |

MENINGITIS continued...

1. WHETHER TO TREAT WITH ANTIBIOTICS

Unless contraindicated, a lumbar puncture should be performed to confirm diagnosis of meningitis.

All patients with suspected or proven meningitis should receive prompt antimicrobial therapy and always within 1 hour of presentation.

2. CHOICE OF ANTIBIOTIC

To ensure complete eradication of meningococcus from the nasopharynx, all patients with meningococcal disease should receive a single dose of ciprofloxacin as soon as they are able to tolerate oral therapy.

Meningitis age 0-1 month:

Once causative organism is known treat as follows:

| ORGANISM | CHOICE OF ANTIMICROBIAL | SUGGESTED DURATION OF THERAPY | NOTES |
|--------------------------------|--|---|--|
| Empirical (organism not known) | IV <u>Cefotaxime</u> + IV <u>Amoxicillin</u> | 21 days depending on severity | |
| Group B Streptococcus | IV <u>Cefotaxime</u> | 14 days | If complicated, continue Cefotaxime for 21 days. |
| Listeria monocytogenes | IV <u>Amoxicillin</u> + IV <u>Gentamicin</u> | 21 days OR until clinical improvement maximum of 7 days | |
| Gram negative bacilli | IV <u>Cefotaxime</u> | 21 days | Longer duration of Cefotaxime if complicated case. |
| Neisseria meningitidis | IV <u>Cefotaxime</u> | 7 days | |
| Haemophilus influenzae | IV <u>Cefotaxime</u> | 10 days | |
| Streptococcus pneumoniae | IV <u>Cefotaxime</u> | 14 days | |
| Herpes simplex | IV <u>Aciclovir</u> | 21 days | Refer to Infectious Diseases / Microbiology for advice on duration |
| Herpes zoster | IV <u>Aciclovir</u> | - | Refer to Infectious Diseases / Microbiology for advice on duration |

MENINGITIS continued...

3. USE OF STEROIDS

Dexamethasone should be given if strong evidence of bacterial meningitis. NICE guidance defines this as:

- frankly purulent CSF
- CSF white blood cell count greater than 1000/μL
- raised CSF white blood cell count with protein concentration greater than 1 g/L
- bacteria on Gram stain.

Do **not** use steroids in children less than 1 month old.

Do **not** start dexamethasone more than 12 hours after starting antibiotics.

Do **not** use steroids if tuberculosis is suspected.

The first dose should be given immediately before, or with the first dose of antibiotics in patients with meningitis with no rash (to exclude those with meningococcal disease). If dexamethasone was not given before, or with the first dose of antibiotics, but was indicated as described above, try to ensure that the first dose of dexamethasone is given within 4 hours of starting antibiotics, but do **not** start dexamethasone more than 12 hours after starting antibiotics.

After the first dose of dexamethasone, discuss the need to continue steroid treatment with a consultant (a longer duration increases the risk of side effects, especially gastrointestinal haemorrhage).

Dosage: Dexamethasone phosphate IV 0.15 mg/kg/dose given four times a day for 2-4 days

4. RECOMMENDATIONS FOR PREVENTION OF SECONDARY CASES AMONG FAMILY CONTACTS

<u>Bacterial meningitis is a notifiable disease. The local Public Health England team should be informed by phone within 24 hours to co-ordinate chemoprophylaxis:</u>

Telephone number - Merseyside (Cheshire and Merseyside HPT):

Monday-Friday 9.00 am-5.00 pm (excluding Bank Holidays) - 0344 225 0562 select option 1

Out of Hours - On call cover 5.00 pm-9.00 am weekdays and all day at weekends and Bank Holidays - Call 0151 434 4819 - Ask for On-call Public Health Contact details for PHE teams in other regions can be found at www.gov.uk/guidance/contacts-phe-health-protection-teams

NEUROSURGERY ANTIBIOTIC TREATMENT GUIDELINES

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---|---|---|--|---|
| INFECTIO | N IN EXTERNAL VENTRICULAR DRAIN | | | | |
| All | Coagulase negative Staphylococcus | INTRAVENTRICULAR Vancomycin | See below | 10 days | |
| INFECTIO | N IN VENTRICULAR SHUNT PENETRATING | CRANIOCEREBRAL INJU | IRIES (INCLUDING DEPRESSED SK | ULL FRACTURE | |
| All | Coagulase negative Staphylococcus Staphylococcus aureus Coliforms Streptococcus spp. Proprionibacterium acnes Corynebacterium spp | IV <u>Cefotaxime</u> + INTRAVENTRICULAR Vancomycin | IV <u>Cefotaxime</u> : refer to BNFc for neonatal doses. All other age groups should have 50mg/kg (max 3g) every 6 hours Intraventricular vancomycin: see below. | 10 days | Remove shunt and replace with plain external ventricular drain (EVD). For intraventricular doses, see notes below. INFECTION IN VENTRICULAR SHUNT |
| PENETRA | TING CRANIOCEREBRAL INJURIES (INCLUI | DING DEPRESSED SKULL | FRACTURE) | | |
| All | Staphylococcus aureus However, the predisposing injury influences the range of potential pathogens. | IV <u>Cefuroxime</u> + IV <u>Metronidazole</u> | IV <u>Cefuroxime</u> 50mg/kg (max 1.5gram) every 8 hours IV <u>Metronidazole</u> : Refer to BNFc | Review at 5 days, duration will depend on whether or not meningitis is present | Debride scalp and skull but only remove superficial brain that is clearly non-viable. Remove readily accessible fragments/foreign bodies. Deeper fragments should not be sought if it means causing damage to the brain. Ensure watertight dural closure; use a periosteal graft or facia lata if needed. Care must be taken in potentially infected situations with artificial dura. |

INTRAVENTRICULAR DRUG DOSES

VANCOMYCIN (prepared doses available from pharmacy):

- Neonate: 10mg once every 24 hours

• Child 1 month-18 years: 10mg once every 24 hours Note: For all children, reduce to 5mg daily if ventricular size reduced or increase to 15 - 20mg once daily if ventricular size increased.

GENTAMICIN: The use of Intraventricular Gentamicin is not recommended

NEUROSURGERY ANTIBIOTIC TREATMENT GUIDELINES (continued)

| | OSUKGEKT ANTIBIOTIC TREATME | , | | | |
|---------|---|---|--|---|--|
| AGE | LIKELY CAUSATIVE | CHOICE OF | DOSE | DURATION OF | NOTES |
| AGE | ORGANISM | ORGANISM ANTIBIOTIC | | THERAPY | NOIES |
| BRAIN A | ABSCESS/SUBDURAL EMPYEMA | | | | |
| All | Streptococcus spp. Enterobacteriaceae Staphylococcus aureus | IV <u>Cefotaxime</u> + IV <u>Metronidazole</u> + (IV <u>Vancomycin</u> if post-trauma or post-op) | For Cefotaxime and Metronidazole doses refer to BNFc and use maximum dose allowed according to age and weight. Refer to local Vancomycin Dosing and Monitoring Guidelines if using Vancomycin | Approx. 6 weeks. A longer duration may be required if the abscess has not been aspirated. | Insert central venous catheter /PICC line Can be converted to IV ceftriaxone once daily and oral metronidazole once the patient has improved (with view to OPAT). Patient may be converted to oral after 2 weeks, if: 1) abscess drained, 2) good clinical response and 3) organism and sensitivities known. |
| POST O | PERATIVE MENINGITIS | | | | |
| All | Empirical therapy | IV <u>Cefotaxime</u> + IV <u>Vancomycin</u> | Refer to BNFc and use maximum dose allowed according to age and weight for Cefotaxime dose. Refer to local IV Vancomycin Dosing and Monitoring Guidelines if using IV Vancomycin | 2-3 weeks depending on clinical response | Consult ID/Micro for optimal therapy choices and duration when causative organism is known |

DENTAL AND MAXILLOFACIAL INFECTIONS

DENTAL ABSCESS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---|----------------------------------|---------------|------------------------|---|
| All ages | Group A Streptococcus Viridans Streptococci Anaerobes | Oral / IV <u>Co-amoxiclav</u> | Refer to BNFc | 5 days | If there is an obvious collection of pus this needs incision and drainage +/- extraction of causative tooth. Choice in penicillin allergy; Clarithromycin plus Metronidazole |

SALIVARY GLAND INFECTION

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|----------------------------------|---------------|------------------------|--|
| All ages | Staphylococcus aureus Streptococci Anaerobes | Oral / IV <u>Co-amoxiclav</u> | Refer to BNFc | 5 days | Consider ultra sound scan to exclude collection of pus within infected gland. Any collection identified may need surgical drainage. Choice in penicillin allergy; Clarithromycin plus Metronidazole |

EAR, NOSE AND THROAT INFECTIONS

ACUTE OTITIS MEDIA

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|-------------------------|---------------|------------------------|---|
| All ages | Streptococcus pneumoniae Haemophilus influenzae | Oral <u>Amoxicillin</u> | Refer to BNFc | 5 days | In patients who do not have severe otitis media, consider delayed antibiotic treatment (collected at parent's discretion after 72 hours if child has not improved). Longer course may be required in very young children or in severe infection. If penicillin allergic, use oral Clarithromycin. |

EPIGLOTTITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---|----------------------|---------------|------------------------|---|
| All ages | Haemophilus influenzae Staphylococcus aureus Streptococcus pneumoniae | IV <u>Cefotaxime</u> | Refer to BNFc | 5 days | Consider oral Co-amoxiclav if well after 3 days of IV therapy unless culture and sensitivity results indicate otherwise, or Clarithromycin if penicillin allergic. If H. influenzae type b is the causative organism discuss the use of chemoprophylaxis for index case and close contacts with Public Health England: Monday-Friday 9.00 am-5.00 pm (excluding Bank Holidays) - 0344 225 0562 option 1 Out of Hours - On call cover 5.00 pm-9.00 am weekdays and all day at weekends and Bank Holidays - Call 0151 434 4819 - Ask for On-call Public Health |

EAR, NOSE AND THROAT INFECTIONS

SINUSITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|-------------------------|---------------|------------------------|---|
| All ages | Streptococcus pneumoniae Haemophilus influenzae | Oral <u>Amoxicillin</u> | Refer to BNFc | 5 days | If penicillin allergic, use oral <u>Clarithromycin</u> . Patients presenting with symptoms for 10 days or less should not be offered antibiotics. Note: The Antimicrobial Stewardship Committee decided to continue with the use of amoxicillin suspension rather than phenoxymethylpenicillin suspension for palatability reasons. |

ACUTE LYMPHADENITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------------|---|----------------------------------|---------------|------------------------|---|
| Greater than 1 month | Staphylococcus aureus Group A Streptococcus Anaerobes | Oral / IV <u>Co-amoxiclav</u> | Refer to BNFc | 7 days | Use IV for severe disease / unable to tolerate orals Switch to oral when tolerating Choice in penicillin allergy: Clarithromycin plus Metronidazole |

ACUTE MASTOIDITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------------|---|---|---|------------------------|--|
| Greater than 1 month | Streptococcus spp. Haemophilus influenzae Moraxella catarrhalis Staphylococcus aureus Anaerobes | IV <u>Cefotaxime</u> + IV <u>Metronidazole</u> | IV Cefotaxime: 50mg/kg (max 3g) every 6 hours Metronidazole: refer to BNFc | 2 weeks | Switch to oral <u>Co-amoxiclav</u> once clinically improving, unless patient is penicillin allergic in which case refer to Infectious Diseases/Microbiology for oral stepdown. |

EAR, NOSE AND THROAT INFECTIONS

CHRONIC MASTOIDITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DURATION OF THERAPY | NOTES |
|----------------------------|---|---|------------------------|---|
| Greater than 1 month | Pseudomonas spp. Escherichia coli Anaerobes Streptococcus spp. Haemophilus influenzae Moraxella catarrhalis Staphylococcus aureus | Dependant on organism isolated, refer to ID/Micro | Minimum of 2 weeks | Following treatment, patients should be observed for a period to monitor for signs of recurrence. If after 3 months post-treatment there are no signs of recurrence then no further treatment will be required. |

TONSILLITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------------|---------------------------|---|---------------|------------------------|--|
| Greater than 1 month | Group A Streptococcus | Oral <u>Amoxicillin</u> Or IV <u>Benzylpenicillin</u> | Refer to BNFc | 7 days | Treat patients with antibiotic only if group A streptococci infection suspected or confirmed. A rapid group A Streptococcus test for tonsillitis is available from the lab. Use <u>Clarithromycin</u> (oral/IV) for 10 days if penicillin allergic. |

PERI-TONSILLAR ABSCESS / RETRO-PHARYNGEAL ABSCESS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------------|---|------------------------|---------------|------------------------|---|
| Greater than 1 month | Staphylococcus aureus Group A Streptococcus Anaerobes | IV <u>Co-amoxiclav</u> | Refer to BNFc | 7 days | Draining the abscess is the best treatment Choice in penicillin allergy: Clarithromycin plus Metronidazole |

GASTRO-INTESTINAL INFECTIONS

CLOSTRIDIOIDES DIFFICILE INFECTION

Note that Clostridium difficile in stool in children is often not the cause of their illness, other tests may be needed and treatment may not be indicated, refer to Infectious Diseases and / or Consultant Microbiologist for advice if C.difficile is suspected.

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---------------------------|------------------------------|---------------|------------------------|---|
| All ages | Clostridium difficile | Oral <u>Metronidazole</u> | Refer to BNFc | 7 - 10 days | Oral vancomycin may be used for patients who cannot tolerate or do not respond to metronidazole, but needs to be extemporaneously prepared by the pharmacy. Relapse is common and should be treated in the same way as the initial episode; it is not believed to be due to antibiotic resistance. |

INTRA-ABDOMINAL INFECTION

INTRA-ABDOMINAL INFECTION

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|-----------------------------|---|--|--|----------------------------------|---|
| Birth to 3 months | Enterobacteriaceae Streptococcus spp. | IV <u>Cefotaxime</u> + IV <u>Metronidazole</u> | Refer to BNFc | 5 days and assess response | |
| Greater than 3 months | Enterobacteriaceae Enterococcus spp. Streptococcus spp. Anaerobes Polymicrobial | IV Piperacillin/Tazobactam In severe sepsis, consider adding a single dose of IV Gentamicin | Refer to BNFc IV Gentamicin is indicated for severe sepsis: Single dose of 7mg/kg (max 420mg), if obese use ideal body weight | 5 days and assess response | Consider switching to oral <u>Co-amoxiclav</u> when appropriate. For Appendicitis, refer to the <u>Appendicectomy Pathway</u> Choice in penicillin allergy: Oral <u>Ciprofloxacin</u> plus <u>Metronidazole</u> |

NECROTISING ENTEROCOLITIS

| TTE OKO III | ACKONSHAD ENTEROCOCINS | | | | | | | |
|-------------|---------------------------|--|--|----------------------------------|--|--|--|--|
| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES | | | |
| All ages | Polymicrobial | IV <u>Cefotaxime</u> + IV <u>Metronidazole</u> In severe sepsis, consider adding a single dose of IV Gentamicin* | Refer to BNFc IV Gentamicin: Refer to local Aminoglycoside Dosing and Monitoring Guidelines on the intranet | 5 days and assess response | *For dosing refer to the appropriate Aminoglycoside Pathway | | | |

RESPIRATORY TRACT INFECTIONS

COMMUNITY ACQUIRED PNEUMONIA

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES | | | |
|----------------------|---|--|---------------|------------------------|--|--|--|--|
| Less than 1 month | Treat as per Sepsis (community acquired) guideline on page 8 | | | | | | | |
| Over 1 month | Streptococcus pneumoniae Haemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae | Mild / Moderate disease: Oral Amoxicillin* Severe disease: Oral Amoxicillin + Oral Clarithromycin | Refer to BNFc | 5 days | Oral antibiotics are as effective as IV for the treatment of severe pneumonia. IV antibiotics should only be considered for patients unable to tolerate oral antibiotics. *When bacterial pneumonia is associated with influenza or measles, Co-amoxiclav is recommended instead of amoxicillin. In Mild / Moderate disease, Clarithromycin is the second line treatment option in penicillin allergy or if there is no response to amoxicillin or co-amoxiclav after 48 hours. See BTS Guidelines on PAEDIATRIC COMMUNITY ACQUIRED PNEUMONIA for further information | | | |

ASPIRATION PNEUMONIA

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------------------|---|----------------------------------|----------------------------|------------------------|--|
| Less than 1 month | | | Treat as per Sepsis (commo | unity acquired) guid | deline on page 8 |
| Over 1 month | Streptococcus pneumoniae Haemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae Anaerobes | IV / oral <u>Co-amoxiclav</u> | Refer to BNFc | 5 days | Choice in penicillin allergy: <u>Ciprofloxacin</u> plus <u>Clindamycin</u> . Avoid the use of clindamycin suspension as poor palatability, consider opening clindamycin capsules or metronidazole if a liquid is required. |

RESPIRATORY TRACT INFECTIONS

HOSPITAL ACQUIRED PNEUMONIA AND COMPLEX CASES (e.g. chronic respiratory conditions, neurodisability etc.)

| TIME OF ONSET | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|---|--|-----------------------------------|--|------------------------|---|
| Early Onset (4 days or less hospitalisation) | | Treat a | s per Community Acquired Pne | eumonia guideline | |
| Late onset (Greater than 4 days hospitalisation) | Often polymicrobial: Staphylococcus aureus Enterobacteriacae Pseudomonas spp Anaerobes Occasionally: Streptococcus pneumoniae Haemophilus influenzae | IV <u>Piperacillin/Tazobactam</u> | IV <u>Piperacillin/Tazobactam</u> 90mg/kg (max 4.5g) every 6 hours | 5 days | Check culture and sensitivity results for oral stepdown. Empirical oral stepdown is Co-amoxiclav unless there is known chronic carriage of Pseudomonas, in which case previous culture and antibiotic sensitivity results should be considered. If penicillin allergic: IV Ciprofloxacin plus IV Clindamycin. When stepping down to oral avoid the use of clindamycin suspension as poor palatability, consider opening clindamycin capsules or Metronidazole if a liquid is required. |

EMPYEMA Refer to **Empyema pathway**

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|---|---|------------------------|---|
| All ages | Streptococcus pneumoniae Haemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae Anaerobes | IV <u>Cefuroxime</u> plus IV <u>Clindamycin</u> | IV <u>Cefuroxime</u> : 50mg/kg (max 1.5g) every 6 hours IV <u>Clindamycin</u> : 10mg/kg (max 1.2g) every 6 hours | 14 days | Refer to Empyema pathway Oral stepdown to Co-amoxiclav unless culture and sensitivities indicate otherwise. Choice in penicillin allergy; Clarithromycin for IV and for oral stepdown |

INFECTIONS IN CYSTIC FIBROSIS Refer to <u>Cystic Fibrosis Management of Infection</u> Guideline INFLUENZA Refer to <u>Use of Antivirals for Influenza Clinical Guideline</u>

SKIN AND SOFT TISSUE INFECTIONS

BURNS - TREATMENT OF INFECTED BURNS Refer to Treatment of infections in children in hospital with burns guideline

| No. of days after burn | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|---|---|---|--|------------------------|---|
| 5 days or less Or 6 – 9 days and no recent history of previous antibiotics | Staphylococcus aureus Group A Streptococcus Gram negative bacilli | IV <u>Cefuroxime</u> If toxic shock; add IV <u>Clindamycin</u> | IV <u>Cefuroxime</u> : 50mg/kg (max 1.5g) every 6 – 8 hrs (refer to BNFc for neonates less than 21 days old) IV <u>Clindamycin</u> : 10mg/kg (max 1.2g) every 6 hours. Refer to BNFc for neonates. | 5 - 10 days | If the patient has been in a hospital in another country in the previous 12 months (Not North America, Northern Europe or |
| 6 – 9 days and recent history of previous antibiotics 10 days or more | As above plus: MRSA Pseudomonas aeruginosa | IV <u>Vancomycin</u> Plus IV <u>Ceftazidime</u> If toxic shock; add IV <u>Clindamycin</u> | IV <u>Vancomycin</u> : Refer to local Vancomycin guidelines. IV <u>Ceftazidime</u> : 50mg/kg (max 2g) every 8 hours. Refer to BNFc for neonates less than 21 days. IV <u>Clindamycin</u> : 10mg/kg (max 1.2g) every 6 hours. Refer to BNFc for neonates. | 5 – 10 days | Australasia) discuss with Microbiology/ Infectious Diseases. Refer to Treatment of infections in children in hospital with burns guideline |

CELLULITIS, ERYSIPELAS, FURUNCLE, SKIN ABSCESS, IMPETIGO

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|-------------------------|--|--|---------------|-------------------------------|--|
| Less than 1 month | Staphylococcus aureus Group A Streptococcus | Mild: Oral <u>Cefalexin</u> Severe: IV <u>Cefotaxime</u> + IV Flucloxacillin | Refer to BNFc | 7 days | Rationalise antibiotics for severe infections at 48 hours |
| Greater than 1 month | Staphylococcus aureus Group A Streptococcus | Mild: Oral Cefalexin liquid or Oral Flucloxacillin caps* if able to swallow capsules If Severe: IV Flucloxacillin | Refer to BNFc | 7 Days Review at 7 days | *Flucloxacillin liquid has a very poor taste If penicillin allergy/MRSA carrier use <u>Clindamycin</u> . If suspension needed consider oral co-trimoxazole. |

SKIN AND SOFT TISSUE INFECTIONS

NECROTISING FASCIITIS

The primary treatment of necrotising fasciitis is surgical debridement and urgent surgical opinion should be sought if suspected

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---|--|---|------------------------|---|
| All Ages | Clostridium perfringens Group A Streptococcus Staphylococcus aureus Escherichia coli | IV <u>Cefotaxime</u> + IV <u>Clindamycin</u> | Refer to BNFc and use maximum doses according to age & weight | 10 days | Start antibiotics within 1 hour of diagnosis for life threatening infections. |

PRE-SEPTAL CELLULITIS and ORBITAL CELLULITIS

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|---|--|---|--|--|
| All ages | Staphylococcus aureus Group A Streptococcus Streptococcus pneumoniae Haemophilus influenzae Anaerobes | IV <u>Cefotaxime</u> * and add IV <u>Metronidazole</u> if there is sinus disease or orbital cellulitis is suspected and refer urgently to ENT. | Refer to BNFc and use maximum doses according to age & weight | 7 days for preseptal cellulitis Longer durations required for orbital cellulitis | Please refer to the Pre-Septal and Orbital Cellulitis Pathway *If considering OPAT for admission avoidance, consider using once daily ceftriaxone instead of cefotaxime. Patient should be referred urgently to ENT if orbital cellulitis is suspected Consider OPAT/switching to oral co-amoxiclav when patient clinically improving. Refer to Micro/ID if penicillin allergic. |

BITES (HUMAN AND ANIMAL)

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|----------------------------------|---------------|------------------------|--|
| All ages | Polymicrobial: Pasteurella spp. Staphylococcus aureus Streptococcus spp. Anaerobes | Oral / IV <u>Co-amoxiclav</u> | Refer to BNFc | 5 days | Check tetanus status, and review need for tetanus booster dose and tetanus immunoglobulin. If penicillin allergy consider <u>Clarithromycin</u> plus <u>Metronidazole</u> |

SURGICAL SITE INFECTIONS

INVOLVING HEAD, NECK, TRUNK OR EXTREMITY

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|--|---------------|------------------------|---|
| All ages | Staphylococcus aureus Group A Streptococcus pyogenes | Mild (minimal erythema/induration and/or pus) Oral Cefalexin Moderate/Severe: IV Cefuroxime | Refer to BNFc | 5 days 7 days | If penicillin allergic, use oral or IV <u>Clindamycin</u> Clindamycin liquid is unpalatable, consider opening capsules. |

INVOLVING AXILLA, PERINEUM, FEMALE GENITAL TRACT OR GI TRACT

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES |
|----------|--|--|---------------|--|--|
| All ggos | Polymicrobial: Staphylococcus aureus Group A Streptococcus | Mild: Oral <u>Co-amoxiclav</u> | Refer to BNFc | 5 days | If penicillin allergic use ciprofloxacin with Clindamycin oral/IV |
| All ages | Enterobacteriaceae Anaerobes Moderate-Severe: IV Co-amoxiclav | Kelel IO BINFC | 7 days | Clindamycin liquid unpalatable, consider opening capsules. | |

URINARY TRACT INFECTIONS

in patients with presumed normal anatomy

CYSTITIS / LOWER UTI

Please also refer to Urinary Tract In-patient Pathway or the Urinary Tract Out-patient Pathway as appropriate

| AGE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTIC | DOSE | DURATION OF THERAPY | NOTES | |
|----------------------|--|-------------------------|---------------|--|-------|--|
| Less than 3 month | Treat as per Sepsis (community acquired) guideline on page 8 | | | | | |
| More than 3month | Enterobacteriaceae | Oral <u>Cefalexin</u> | Refer to BNFc | If oral antibiotic cannot be used, administer Cefotaxime. 3 days Trimethoprim is an alternative in cephalosp allergy (unless already on trimethoprim prophylaxis). | | |

COMPLICATED UTI (UPPER UTI/ UROSEPSIS)

Please also refer to <u>Urinary Tract In-patient Pathway</u> or the <u>Urinary Tract Out-patient Pathway</u> as appropriate

| AGE | AGE LIKELY CAUSATIVE ORGANISM | | DF DOSE | DURATION OF THERAPY | NOTES | |
|-----------------------|--|---|---------------|------------------------|---|--|
| Less than 3 months | Treat as per Sepsis (community acquired) guideline on page 8 | | | | | |
| More than 3 months | Enterobacteriaceae | IV <u>Cefotaxime</u> Oral stepdown to oral <u>Cefalexin</u> | Refer to BNFc | 7-10 days | Ciprofloxacin is an alternative in penicillin/cephalosporin allergy. Always use a different antibiotic for treatment than that used for prophylaxis. | |

Antibiotic prophylaxis should not routinely be offered for a first time UTI, but may be considered in infant and children with recurrent UTI.

Always use a different antibiotic for treatment than that used for prophylaxis.

Part II: SURGICAL PROPHYLAXIS GUIDELINES

GENERAL PRINCIPLES OF SURGICAL PROPHYLAXIS

- **Penicillin allergy** patients with a history of anaphylaxis, urticaria or rash immediately after penicillin administration should not receive a penicillin or cephalosporin. Discuss alternative antibiotic treatment with Microbiology/ Infectious Diseases team unless an alternative has been suggested in this document.
- Carriage of Methicillin Resistant Staphylococcus Aureus (MRSA):
 - if the patient is known to have/has had MRSA, ADD Teicoplanin to the antibiotic regimen specified in the guidelines, and in elective surgery prescribe topical Mupirocin 2% nasal ointment tds to anterior nares and Octenisan® washes daily for 5 days, with surgery at day 5.
- Carriage of other multi-resistant organisms: use standard antimicrobial prophylaxis recommended in the guidelines
- Antibiotics for surgical prophylaxis should be administered on induction
- If patient is already receiving treatment antibiotics but has not received doses of antibiotics in the previous hour; betalactams such as cefotaxime, cefuroxime, co-amoxiclav and piperacillin/tazobactam can be re-dosed on induction due to short half-life (this does not apply to ciprofloxacin, metronidazole, clindamycin, gentamicin, metronidazole or teicoplanin).
- Major blood loss (>20 ml/kg): additional dosage of prophylactic antibiotic should be considered after fluid replacement.
- **Prolonged surgery:** additional doses of antibiotic should be considered as indicated in the tables on the next page.
- If an antibiotic is to be continued post-op: the first post-op dose should be given after a "normal dosing interval" from the last intra-operative dose (e.g. antibiotic with "normal dosing frequency" of 8 hours, given on induction at 9am, re-dosed at 12noon during prolonged surgery, therefore first post-op dose due at 8pm).
- All prescriptions for surgical prophylaxis should have a stop date when prescribed.
- Prophylaxis against infective endocarditis is NOT recommended in the following circumstances:
 - For patients undergoing dental procedures
 - For patients undergoing non-dental procedures at the following sites: upper and lower GI tract; GU tract (this includes urological, gynaecological and obstetric procedures and childbirth); upper and lower respiratory tract (this includes ear, nose and throat procedures and bronchoscopy)
- Prophylaxis against infective endocarditis IS recommended in the following circumstances:
 - If a patient at risk of infective endocarditis is having a GI or GU procedure at a site where there is suspected infection; give a single dose of Teicoplanin at induction AS WELL AS the usual antibiotic prophylaxis for the surgery

ANTIBIOTIC DOSES AND REDOSING ADVICE FOR SURGICAL PROPHYLAXIS

Antibiotic doses assume children have normal renal function. Doses may require modification in renal impairment. Consult the BNF for Children for further details on dosing.

Intraoperative dosing table for Neonates

| ANTIBIOTIC | PRE AND INTRAOPERATIVE DOSES FOR NEONATES | ADMINISTRATION | INTRAOPERATIVE REDOSING |
|----------------------|--|-----------------------------|-------------------------|
| <u>Cefotaxime</u> | 50mg/kg | Slow IV bolus injection | N/A |
| <u>Cefuroxime</u> | 50mg/kg | Slow IV bolus injection | N/A |
| Clindamycin | 5mg/kg | IV infusion over 15 mins | Every 8 hours |
| <u>Co-amoxiclav</u> | 30mg/kg | Slow IV bolus injection | N/A |
| Gentamicin | 5mg/kg If continuing post-op, check level after 24hrs to ensure <1mg/L, then refer to aminoglycoside pathway for dosing advice | Slow IV bolus injection | N / A |
| <u>Metronidazole</u> | Neonate with gestational age under 40wks: 10mg/kg Neonates with gestational age 40wks and above: 20 - 30mg/kg | IV infusion over 20 mins | N / A |
| <u>Teicoplanin</u> | 16mg/kg | IV infusion over 30 mins | N/A |

Intraoperative dosing table for children over 44 weeks corrected gestational age

| ANTIBIOTIC | PRE AND INTRAOPERATIVE DOSE FOR CHILDREN OVER 44 WEEKS CORRECTED GESTATIONAL AGE | ADMINISTRATION | INTRAOPERATIVE REDOSING | |
|-----------------------------|---|-----------------------------|----------------------------|--|
| <u>Cefuroxime</u> | 50mg/kg (max 1500mg) | Slow IV bolus injection | Every 3 hours | |
| Ciprofloxacin | 10mg/kg (max 400mg) | IV infusion over 60mins | N/A | |
| Co-amoxiclav | 30mg/kg (max 1200mg) | Slow IV bolus injection | Every 3 hours | |
| Clindamycin | 5mg/kg | IV infusion over 15 mins | Every 6 hours | |
| Gentamicin | 2.5mg/kg If continuing post-op, check level after 8hrs to ensure <1mg/L, then refer to aminoglycoside pathway for dosing advice | Slow IV bolus injection | N /A | |
| <u>Metronidazole</u> | Age 1 month – 12 years: 30mg/kg (max 500mg) Age 12 – 18 years: 500mg | IV infusion over 20 mins | N/A | |
| Piperacillin/ Tazobactam | Age 1 month – 2years: 90mg/kg Age over 2 years: 112.5mg/kg (max 4.5gram) | Slow IV bolus injection | Every 3 hours | |
| <u>Teicoplanin</u> | 1 - 2 months: 16mg/kg | IV infusion over 30 minutes | N. / A | |
| <u>reicopidriiri</u> | Older than 2 months: 10mg/kg (max 800mg) | Slow IV bolus injection | N/A | |

CARDIAC SURGICAL PROPHYLAXIS GUIDELINES

| PROCEDURE | LIKELY PATHOGENS | CHOICE OF ANTIBIOTICS | DURATION OF POST-OP THERAPY | DOSING/NOTES |
|--|-------------------------------------|---|--|---|
| Cardiac Surgery (7 days old or less) | Staphylococcus aureus | IV <u>Cefuroxime</u> | 24 hours (2 doses) (unless chest open) | Give 50mg/kg at induction 50mg/kg/dose every 12 hours (first PICU dose to be given 12 hours after last theatre dose) |
| Cardiac surgery (Greater than 7 days old) | Staphylococcus aureus | IV <u>Cefuroxime</u> | 24 hours (3 doses) (unless chest open) | Give 50mg/kg (max 1.5g) at induction 50mg/kg/dose (max 1.5g) every 8 hours (first PICU dose to be given 8 hours after last theatre dose) |
| If cl | nest open (with or without ECMO) co | ntinue antibiotics until chest closure, | refer to guidance below for chest c | |
| Chest Closure or chest exploration on PICU | Staphylococcus aureus | IV <u>Cefuroxime</u> | Dose pre and post procedure | Give 50mg/kg/dose (maximum 1.5g) 30 minutes prior to procedure (give only if cefuroxime dose administered greater than 3 hours previously) Second dose of 50mg/kg (maximum 1.5g) to be administered: 12 hours later if neonate 0- 7days 8 hours later if greater than 7 days |

In the case of **penicillin / cephalosporin allergy** use IV teicoplanin plus IV gentamicin as an alternative to cefuroxime (see page 33)

CARDIAC SURGICAL PROPHYLAXIS GUIDELINES (continued)

For teicoplanin/gentamicin – follow dosing regimen below.

If teicoplanin and/or gentamicin are used - do not re-dose every 3 hours in prolonged surgery or give doses pre/post chest closure/exploration.

| CHOICE OF ANTIBIOTICS | DURATION OF POST-OP THERAPY | DOSING |
|---|--|---|
| | | Teicoplanin: 16mg/kg on induction followed by ONE dose of 8mg/kg 24 hours later (administer as a 30 minute infusion). plus Gentamicin: 4mg/kg on induction, check pre dose level after 22 – 24 hours, ensure level is less than 2mg/L, before giving ONE more dose of 4mg/kg. |
| IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> | 24 hours (unless chest Open) | If chest open continue up to and including day of chest closure with: Teicoplanin: 16mg/kg on induction followed by 8mg/kg every 24 hours thereafter (administer as a 30 minute infusion) plus Gentamicin: 4mg/kg on induction, check pre dose level after 22 – 24 hours, ensure level is less than 2mg/L, before continuing with 4mg/kg every 24 hours (also check pre dose and 1 hour post levels at 3 rd dose, and every 2 – 3 days thereafter, or more frequently if clinically indicated e.g. in patients with renal dysfunction). |
| IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> | 24 hours (unless chest Open) | Teicoplanin: 1 – 2 months: 16mg/kg on induction followed by 8mg/kg every 24 hours thereafter Older than 2 months: 10mg/kg (max 800mg) on induction followed by 10mg/kg (max 800mg) every 12 hours for a further TWO doses plus Gentamicin: 3mg/kg on induction, check pre dose level 12 hours later, ensure level less than 1mg/L before giving 7mg/kg as a 20 minute infusion for ONE dose only. If chest open continue up to and including day of chest closure with: Teicoplanin: Dose as above. plus Gentamicin: 3mg/kg on induction, check pre dose level 12 hours later, ensure level less than 1mg/L before starting 7mg/kg as a 20 minute infusion every 24 hours as per |
| | IV Teicoplanin plus IV Gentamicin IV Teicoplanin plus | IV Teicoplanin plus (unless chest Open) IV Teicoplanin plus (unless chest Upen) IV Teicoplanin plus (unless chest Upen) |

CARDIAC PACEMAKER INSERTION

This guideline refers to: endo-cardiac and epi-cardiac pace-maker implantations, new implantations, battery replacements, with or without lead(s) replacements

| AGE | LIKELY PATHOGENS | CHOICE OF ANTIBIOTICS | DURATION OF THERAPY | NOTES |
|---|---|---|--|---|
| Gestational age: less than 32 weeks | Staphylococcus aureus Coagulase - negative Staphylococcus | IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> | Teicoplanin: 16mg/kg on induction, followed by 8mg/kg after 24hrs plus Gentamicin: 4mg/kg on induction only | Disinfect the skin by swabbing with chlorhexidine alcohol solution 3 times. If teicoplanin or gentamicin are contra-indicated or unavailable, IV cefuroxime can be used. See CHOICE OF ANTIBIOTIC below for dosage. |
| Gestational age: 32 weeks to 44 weeks | Staphylococcus aureus Coagulase - negative Staphylococcus | IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> | Teicoplanin:16mg/kg on induction, followed by 8mg/kg after 24hrs plus Gentamicin: 4mg/kg on induction followed by 4mg/kg after 24hrs | Disinfect the skin by swabbing with chlorhexidine alcohol solution 3 times. If teicoplanin or gentamicin are contra-indicated or unavailable, IV cefuroxime can be used. See CHOICE OF ANTIBIOTIC below for dosage. |
| 1 month to 18 years | Staphylococcus aureus Coagulase - negative Staphylococcus | IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> | Teicoplanin: See notes plus Gentamicin: 3mg/kg on induction followed by 3mg/kg after 12hrs and 24hrs | Disinfect the skin by swabbing with chlorhexidine alcohol solution 3 times. Teicoplanin: 1 – 2months: 16mg/kg on induction, followed by 8mg/kg after 24hrs Older than 2 months: 10mg/kg (max 800mg) on induction followed by 10mg/kg (max 800mg) every 12 hours for a further TWO doses If teicoplanin or gentamicin are contra-indicated or unavailable, IV cefuroxime can be used. See CHOICE OF ANTIBIOTIC below for dosage. |

CLEFT LIP AND PALATE SURGICAL PROPHYLAXIS

| | PROCEDURE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTICS | DURATION OF THERAPY | NOTES / DOSING INFORMATION |
|---|--|--|-----------------------|---------------------|--|
| • | Primary Lip & Palate Repairs Secondary Lip & Palate Repairs (Revisions) | Staphylococcus aureus Streptococcus spp | IV <u>Cefuroxime</u> | Single Dose | |
| • | Bone Grafting Procedures | Staphylococcus aureus Streptococcus spp | IV <u>Cefuroxime</u> | 24 hours | Neonates: 0-7 days 50mg/kg, 12 hourly for total of 2 doses Neonates less than 7 days and all other ages: 50mg/kg, 8 hourly for a total of 3 doses (maximum 1.5g/dose) |

In cases where there is **penicillin / cephalosporin allergy or anaphylaxis to penicillin** use IV <u>Teicoplanin</u> as an alternative to cefuroxime

EAR, NOSE AND THROAT SURGICAL PROPHYLAXIS

| PROCEDURE | LIKELY ORGANISM | CHOICE OF ANTIBIOTICS | DURATION | NOTES |
|--|---|--|-------------|-------|
| Clean head & neck surgery (Incl. radical neck dissection) | | Prophylaxis not | recommended | |
| Contaminated/ clean- contaminated head & neck surgery | Staphylococcus aureus Streptococcus spp. Anaerobes | IV <u>Cefuroxime</u> +/- IV <u>Metronidazole</u> | Single Dose | |
| Tracheostomy | Prophylaxis not recommended | | | |
| Grommet insertion With dry ear | | Prophylaxis not | recommended | |
| Grommet insertion with infected ear | Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis | Ciprofloxacin 0.3% ear drops | x 5 days | |
| Adenoidectomy Suction diathermy Coblation Traditional (curette) | Prophylaxis not recommended | | | |
| Tonsillectomy Traditional Coblation | Prophylaxis not recommended | | | |

In cases where there is **penicillin / cephalosporin allergy** use IV <u>Teicoplanin</u> as an alternative to cefuroxime

EAR, NOSE AND THROAT SURGICAL PROPHYLAXIS (continued)

| PROCEDURE | LIKELY ORGANISM | CHOICE OF ANTIBIOTICS | DURATION | NOTES |
|---|---|---|----------------------|--|
| Mastoidectomy for acute mastoiditis | Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis Group A Streptococcus Staphylococcus aureus | IV <u>Cefuroxime</u> +/- Ciprofloxacin 0.3% ear drops | Single dose | Refer to acute mastoiditis treatment guidelines |
| Mastoidectomy +/- Choleasteatomy | Prophylaxis not recommended | | | |
| Foreign body removal | Prophylaxis not recommended | | | |
| Nose or sinus surgery Reduction of nasal fracture Septoplasty Septorhinoplasty Intranasal polypectomy Submucosal Diathermy to the Inferior Turbinates (SMDIT) Endoscopic sinus surgery | Prophylaxis not recommended | | | |
| Epistaxis Anterior – Merolell | Staphylococcus aureus | IV <u>Co-amoxiclav</u> If packing left greater than 24hours | Until aguzo romovo d | |
| Epistaxis Posterior – ballon/foleys | Streptococcus spp | No prophylaxis | Until gauze removed | |

In cases where there is **penicillin / cephalosporin allergy** use IV <u>Teicoplanin</u> as an alternative to cefuroxime

GASTRO-INTESTINAL SURGICAL PROPHYLAXIS

| PROCEDURE | POTENTIAL PATHOGENS | ANTIBIOTICS | DURATION | NOTES |
|---------------------------------|--|--|--|--|
| Appendicectomy | Enterobacteriaceae Staphylococcus aureus Anaerobes | IV <u>Piperacillin/</u> <u>Tazobactam</u> | Refer to <u>Appendicectomy</u> <u>pathway</u> | Refer to <u>Appendicectomy</u> <u>pathway</u> regarding treatment antibiotics |
| Clean and Clean-contaminated | Enterobacteriaceae Staphylococcus aureus Anaerobes | IV <u>Co-amoxiclav</u> | Single dose | |
| Contaminated | Enterobacteriaceae Staphylococcus aureus Anaerobes | IV <u>Co-amoxiclav</u> | 48 hrs | Consider for heavily contaminated surgery involving lower GI tract. |
| Therapeutic endoscopy | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | Refers to additional therapy procedure performed besides the routine endoscopy. Examples include insertion of PEG and removal of polyps. |
| Diagnostic endoscopy | Surgical prophylaxis not recommended | | | |

In the case of **penicillin allergy** use IV <u>Clindamycin</u> plus IV <u>Gentamicin</u>

NEUROSURGERY AND CRANIOFACIAL SURGICAL PROPHYLAXIS

| PROCEDURE | LIKELY CAUSATIVE ORGANISM | CHOICE OF ANTIBIOTICS | DURATION OF THERAPY | NOTES |
|---|--|--|--|--|
| Clean non-implant surgery and clean implant surgery | Staphylococcus aureus | IV <u>Cefuroxime</u> | Single dose | |
| Clean - contaminated procedures | Staphylococcus aureus Streptococcus pneumoniae Anaerobes | IV <u>Cefuroxime</u> plus IV <u>Metronidazole</u> | Single dose of each | |
| CSF shunt surgery | Staphylococcus aureus | IV <u>Cefuroxime</u> plus INTRAVENTRICULAR Vancomycin | Single dose of each at induction | |
| Spinal surgery | Staphylococcus aureus | IV <u>Cefuroxime</u> | Single dose | |
| Craniofacial procedures | Staphylococcus aureus | IV <u>Cefuroxime</u> + / - IV <u>Metronidazole</u> | 24 hours | Add metronidazole for procedures that cross the naso or oropharynx |

In cases where there is **penicillin / cephalosporin allergy** use IV <u>Teicoplanin</u> as an alternative to cefuroxime

INTRAVENTRICULAR DRUG DOSES

VANCOMYCIN (prepared doses available from pharmacy):

- Neonate: 10mg once every 24 hours
- Child 1 month-18 years: 10mg once every 24 hours

Note: For all children, reduce to 5mg daily if ventricular size reduced or increase to 15-20mg once daily if ventricular size increased.

ORTHOPAEDIC AND SPINAL SURGICAL PROPHYLAXIS

| CONDITION | LIKELY PATHOGENS | ANTIBIOTICS | DURATION | COMMENTS |
|---|--|----------------------|--------------|--|
| Clean orthopaedic surgery without insertion of implants | Prophylaxis not required | | | |
| Clean orthopaedic surgery <u>with</u> insertion of implants | Staphylococcus aureus | IV <u>Cefuroxime</u> | Single dose | |
| Contaminated Orthopaedic surgery | Staphylococcus aureus Gram negative bacilli | IV <u>Cefuroxime</u> | Up to 3 days | Prompt initiation of antibiotics on arrival in A&E is a priority, which should be continued until soft tissue closure or for a maximum of 3 days, whichever is shorter. A single dose of IV <u>Teicoplanin</u> 10mg/kg (max 800mg) and a single dose of IV <u>Gentamicin</u> to be given at wound closure. Assess need for tetanus immunisation. |
| Spinal Surgery | Staphylococcus aureus | IV <u>Cefuroxime</u> | 48 hours | Refer to spinal surgery pathway |

In cases where there is **penicillin / cephalosporin allergy** use IV <u>Teicoplanin</u> (plus IV <u>Gentamicin</u> for contaminated surgery) as an alternative to cefuroxime

URO-GENITAL SURGICAL PROPHYLAXIS

| PROCEDURE | LIKELY PATHOGENS | ANTIBIOTIC | DURATION | NOTES |
|--|---------------------------------|--------------------------|---------------|--|
| Circumcision | | Prophylaxis no | t recommended | |
| Cystoscopy | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| Hypospadias repair | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | If urinary catheter left in situ then administer oral Trimethoprim until catheter is removed |
| Hydrocoele / hernia repair | | Prophylaxis no | t recommended | |
| Shock wave lithotripsy | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| Endoscopic ureteric stone fragmentation/removal | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| Nephrectomy | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | Prophylaxis not recommended unless patient has recurrent urinary tract infections |
| Pyeloplasty (with / without stent) | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| Reconstructive surgery (involving bowel) | Enterobacteriaceae Anaerobes | IV <u>Co-amoxiclav</u> | Single dose | |
| Surgery for vesicoureteric reflux (endoscopic or open) | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| Urethroplasty | Enterobacteriaceae | IV <u>Co-amoxiclav</u> | Single dose | |
| MCUG (Micturating cystourethrogram) | Enterobacteriaceae | Oral <u>Trimethoprim</u> | 3 days* | *To be started 24 hours before the procedure |

In cases where there is **penicillin / cephalosporin allergy** use IV <u>Teicoplanin</u> plus IV <u>Gentamicin</u> as an alternative to co-amoxiclav

Appendix I: RESTRICTED ANTIMICROBIALS

RESTRICTED ANTIMICROBIALS

The use of the antimicrobials in the table below should be restricted in order to minimise the development of antimicrobial resistance. Only Consultants from the specialties indicated in the table can approve the use of these antimicrobials and their recommendation must be documented in the case notes along with the following information: a) Indication b)Evidence of an assessment of severity (may include temperature, heart rate, respiratory rate, blood pressure, white cell count, CRP) c) Evidence of appropriate cultures being taken (preferably before starting antimicrobials).

| Antimicrobial | Infectious Diseases/ Microbiology | Oncology (according to guidelines) | Respiratory (according to guidelines) | PICU |
|------------------------|--------------------------------------|--|---|------|
| Liposomal Amphotericin | ✓ | 1 | | |
| Caspofungin | * | | | |
| IV Colistin | 1 | | | |
| Daptomycin | 1 | | | |
| Ertapenem | 1 | | | |
| Fosfomycin | ✓ | | | |
| Levofloxacin | * | | | |
| Linezolid | 1 | | | |
| Micafungin | * | | | |
| Meropenem | * | * | • | |
| Temocillin | * | | | |
| Tigecycline | * | | | |
| Pivmecillinam | * | | | |
| Voriconazole | * | 1 | | |

RESTRICTED ANTIMICROBIALS DOSE INFORMATION

Doses for the following restricted antimicrobials are not listed in the BNFc or the manufacturer's summary of product characteristics. Instead we have based our dose recommendations on the limited evidence available.

| RESTRICTED ANTIMICROBIAL | RECOMMENDED DOSE | NOTES |
|---|--|---|
| IV Daptomycin | IV bolus or short infusion Less than 3 months: 6mg/kg/dose every 12 hours 3 months – 2 years: 10mg/kg/dose every 24 hours 2 – 6 years: 9mg/kg every 24 hours 7 – 11 years: 7mg/kg every 24 hours 12 – 17 years: 5mg/kg every 24 hours (consider using adult dose for infective endocarditis: 6mg/kg daily) | Measure baseline serum creatine kinase and monitor weekly thereafter due to risk of myopathy. Pre-dose and 1-hour post-dose levels are required for patients with renal impairment or creatine kinase elevation. Measure levels around the 3rd or 4th dose and send to Bristol Antimicrobial Reference Laboratory via the Biochemistry department. Target predose level is 5 – 20mg/L. Bristol will advise an appropriate range for 1-hour post dose levels. |
| Oral Fosfomycin Calcium 250mg/5ml liquid | Preterm neonates and children<1year: 150-300mg every 8 hours Children greater than 1 year: 250-500mg every 8 hours Adults: 500mg-1g every 8 hours | |
| Oral Fosfomycin trometamol 3 gram sachets | Age less than 1 year: Uncomplicated cystitis: 1g single dose orally Age 1-12 years: Uncomplicated cystitis: 2g single dose orally Greater than 12 years: Uncomplicated cystitis: 3g single dose orally. | If this product is used for recurrent cystitis, consider repeating the dose at 3 day intervals. |
| IV Levofloxacin | IV Infusion Age 6 months-5 years: 10mg/kg/dose twice daily Age greater than 5 years: 10mg/kg once daily (maximum single dose is 500mg) Adults: 500mg once or twice daily. | |
| Oral Levofloxacin | Age 6 months-5 years: 10mg/kg/dose twice daily Age greater than 5 years: 10mg/kg once daily (maximum single dose is 500mg) Adults: 500mg once or twice daily. | Available as 250mg tablets. Pharmacy can also formulate a 250mg/5ml liquid if required. |
| IV Micafungin | IV infusion Age up to 4 months (including neonates): - 10mg/kg once daily* Age greater than 4 months: Dose as per BNFc | *If central nervous system (CNS) infection is suspected 10 mg/kg dose should be used due to the dose-dependent penetration of micafungin into the CNS. The safety and efficacy in children less than 4 months of age on doses of 4 and 10 mg/kg for the treatment of invasive candidiasis with CNS involvement has not been established in clinical studies. |
| Oral Pivmecillinam 200mg tablets | Dose as per BNFc but consider that this product is only available as a 200mg tablet, which can be cut into 100mg portions and crushed before adding to a small amount of food or administration via an enteral feeding tube. | |
| IV Temocillin | IV bolus or short infusion Age 6months and above: 25mg/kg (max 2g) every 12 hrs | |
| IV Tigecycline | IV infusion Age less than 8yrs: NOT TO BE USED Age 8 to less than 12yrs: 1.2mg/kg (max 50mg) every12hrs Age 12-18 years: 50mg every 12 hours | |

REFERENCES

Start Smart then Focus: antimicrobial stewardship toolkit for English hospitals, DoH 2011 (updated 2015)

Antimicrobial Stewardship: systems and processes for effective antimicrobial use. NICE Guideline 15 (2015)

Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter Related Infection. L.A. Mermel et al. Clinical Infectious Diseases 2009;49:1–45

Bacterial meningitis and meningococcal septicaemia. NICE Clinical Guideline 102; September 2010 (updated Feb 2015)

<u>British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011</u>
M. Harris et al, On behalf of the British Thoracic Society Standards of Care Committee. Vol. 66 Suppl(2) Thorax Oct 2011.

Managing Bone and Joint Infection in Children. Faust et al. Arch Dis Child. 2012;97(6):545-553

Urinary tract infection in under 16s diagnosis and management, NICE Clinical Guideline 54 2007 (updated 2017)

Surgical site infections: prevention and treatment, Clinical Guideline 74 (2008) updated 2017.

<u>Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures</u> NICE Clinical Guideline 64 (2008) updated 2016.

Antibiotic prophylaxis in surgery. SIGN Guideline 104 (2008) updated 2014.

Clinical Practice Guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 2013; 70:195-283

Summary of Product Characteristics for Cubicin powder for concentrate for solution for injection or infusion. Published by Merck Sharp & Dome (accessed 7th April 2017, last updated 11th July 2016).

Summary of Product Characteristics for Fosfocina. Published by Labarotorios ERN (accessed 7th April 2017).

Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. Falagas et al. Journal of Antimicrobial Chemotherapy 2010; 65: 1862–1877

Comparative study of levofloxacin in the treatment of children with community acquired pneumonia. Pediatrc Infectious Diseases Journal 26(10)868-878

Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatric Infectious Diseases Journal 26(10)879-891

Summary of Product Characteristics for Mycamine 50mg and 100mg powder for solution and infusion. Published by Astellas Pharma (Accessed 7^{th} April 2017, last updated 22^{nd} July 2016).

Temocillin in the treatment of pyelonephritis in children. Drugs Exp Clin Res. 1987;13(3):171-3.

Summary of Product Characteristics for Tygacil 50mg powder for solution or infusion. Published by Pfizer (accessed 7th April 2017, last updated 23rd June 2016).



| Antimicrobial Prescribing Guidelines | | | | |
|--------------------------------------|---|--|--|--|
| Version: | 6 | | | |
| Ratified by: | Clinical Development Evaluation Group | | | |
| Date ratified: | 16 th April 2021 | | | |
| Name of originator/author: | Kelly McGrail (Antimicrobial Pharmacist) | | | |
| Name of responsible committee: | Antimicrobial Stewardship Group (ASG) | | | |
| Name of executive sponsor: | N/A | | | |
| Key search words: | ABSCESS, Antibiotic, Antibiotics, Antimicrobial, Antimicrobials, Bite, Bites, Burn, Burns, Cellulitis, Cystitis, DENTAL ABSCESS, Infective endocarditis, ENDOCARDITIS, Empyema, Infection, Infections, Empirical, Epiglottitis, LYMPHADENITIS, MASTOIDITIS, NECROTISING ENTEROCOLITIS, NECROTISING FASCIITIS, Surgical Prophylaxis, Surgical site infection, Otitis media, Pre-septal cellulitis, Orbital cellulitis, Prophylaxis, PERI-TONSILLAR ABSCESS, Pneumonia, pyelonephritis, RETRO-PHARYNGEAL ABSCESS, CLOSTRIUM DIFFICILE, Restricted, SALIVARY GLAND INFECTION, Sepsis, Septic, Septic arthritis, Septicaemia, Sinusitis, TONSILLITIS, Meningitis, Osteomyelitis, UTI, Urinary tract infection | | | |
| Date issued: | 16 th April 2021 | | | |
| Review date: | April 2024 | | | |

| Version Control Table | | | | | |
|-----------------------|----------|--|----------|---|--|
| Version | Date | Author(s) | Status | Comment(s) | |
| 6 | April 21 | K McGrail | Current | Inclusion of High Dose Antibiotic Table | |
| 5 | May 18 | A Taylor, D Porter, A Riordan | Archived | | |
| 4 | Nov 17 | A Taylor | Archived | Reverted back to Aug 17 version | |
| 3 | Oct 17 | A Taylor, D Porter | Archived | | |
| 2 | Aug 17 | D Sharpe, S Paulus, A Riordan, D Porter | Archived | | |
| 1 | Jun 17 | D Sharpe, S Paulus, A Riordan, D Porter | Archived | To improve access to local antimicrobial prescribing guidelines the following existing docs have been combined into a single file: the empirical treatment guidelines, cardiac surgical prophylaxis guidelines, cardiac pacemaker insertion prophylaxis guidelines, cleft lip and palate surgical prophylaxis, ear, nose and throat surgical prophylaxis, gastrointestinal surgical prophylaxis, neurosurgery and craniofacial surgical prophylaxis, orthopaedic and spinal procedures surgical prophylaxis, uro-genital surgical prophylaxis and the restricted antimicrobials list. | |

| Review and Revision(s) Log | | | | | | |
|--|--------|---|--|--|--|--|
| Record of revision(s) made to guidelines since Version 1 | | | | | | |
| Section | Page | Davisian/s) mada | Reason for revision(s) | | | |
| Number | Number | Revision(s) made | | | | |
| Part I | 7 | Inclusion of High Dose Antibiotic Table | To provide dosing advice for specific | | | |
| | | (April 2021) | infections as per the most recent EUCAST | | | |
| | | | guidance. | | | |
| | Mar 18 | To Sepsis (Community/Hospital Acquired) | In line with current practice | | | |
| | | To Sinusitis | In line with decision to follow NICE | | | |
| | | | guidance | | | |
| | | Necrotising enterocolitis | To reflect current practice | | | |
| | | Teicoplanin dosing cap increased to 800mg | | | | |
| | | (max dose that can be given by IV bolus) | | | | |
| | | Restricted Antimicrobial list | | | | |